Nivolumab exposure and tumor-size dynamics
An exposure-response model connecting nivolumab steady-state exposure to competing tumor shrinkage and progression processes and their resulting tumor-size trajectory.
- Therapeutic
- Nivolumab
- Target
- PD-1 / PDCD1
- Disease
- Non-small cell lung cancer
Biological model
An exposure-response model connecting nivolumab steady-state exposure to competing tumor shrinkage and progression processes and their resulting tumor-size trajectory.
Model details
An exposure-response model connecting nivolumab steady-state exposure to competing tumor shrinkage and progression processes and their resulting tumor-size trajectory.
Modeled states
- elapsed time weeksweek
Modeled dynamic state for elapsed time weeks.
- exploratory elapsed weeksweek
Modeled dynamic state for exploratory elapsed weeks.
- exploratory tumor size mmmm
Modeled dynamic state for exploratory tumor size mm.
- tumor size percent baselinepercent
Modeled dynamic state for tumor size percent baseline.
Key readouts
- Steady-state trough concentrationunknown
Model-derived readout for steady-state trough concentration.
- Tumor sizemm
Model-derived readout for tumor size.
- Tumor size relative to baselinepercent
Model-derived readout for tumor size relative to baseline.
- elapsed time weeksweek
Model-derived readout for elapsed time weeks.
- exploratory elapsed weeksweek
Model-derived readout for exploratory elapsed weeks.
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
joint MEL 3 mg/kg, Cminss 85 ug/mL
How does nivolumab exposure shift the balance between tumor shrinkage and progression? Explore this biological starting configuration through Steady-state trough concentration, Tumor size, Tumor size relative to baseline. This is a mechanistic product exploration, not a paper-result reproduction.
Questions to explore
- How does nivolumab exposure shift the balance between tumor shrinkage and progression?
Starting result
This result reflects the starting settings. Run your changes to update it.
Model inputs
Five scientist-facing controls at most.
Compare a parameter
How does one model input change the response?
How does nivolumab exposure shift the balance between tumor shrinkage and progression?
exploratory cminss ug mL
Model parameter controlling exploratory cminss ug ml.
Exploratory range around the default value.
5 evenly spaced values in ug/mL. Other model inputs and the simulation window stay fixed.
Interpret with care
- Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
- Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.
Review the server-confirmed fixed price before starting the comparison.
Comparative response
End-of-window response across the selected parameter values.
Choose an exploratory range around the default, review the fixed price, and run the comparison.
Scientific reference
Supporting publication
Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapyJournal for ImmunoTherapy of Cancer
